Search bioRxiv⌕ Search

Biology subjects

Dey, A. K.

Publications and source records attributed to Dey, A. K..

4 recordsLinked to original sources

Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) platform provides unique antigen delivery system through controlled release to improve immune response to vaccination

Prophylactic vaccines are commonly delivered using a multi-dose regimen with the goal of generating potent, durable protection against a specific pathogen. However, the requirement for multiple administrations can impede patient adherence and reduce overall protection. Designing a single-shot vaccine without compromising efficacy could significantly improve vaccine adherence and performance. Previously, it has been shown that atomic-layer deposition (ALD) of alumina (Al2O3) can be applied to spray dried, thermostabilized antigen-containing powders to produce alumina-coated vaccine particles that, when compared to a liquid control, elicit improved humoral immunity with response kinetics controlled by ALD-coat thickness. However, previous studies have not defined the particle release/antigen delivery profile of ALD-coated vaccines. The studies in this manuscript were designed to investigate how the kinetics of antigen release from ALD-coated vaccines impacts the timing and magnitude of the immune response relative to single- and multi-dose liquid vaccine regimens using two distinct antigens, Ovalbumin and the HIV-1 envelope trimer, N332-GT5 gp140. By combining longitudinal in vivo imaging and immunological readouts, we demonstrate that ALD-coated vaccines exhibit tunable, variable-rate release and deliver antigen in a unique, prolonged manner that results in an improved immune response to single-shot vaccination for difficult to target pathogens, such as HIV-1. Furthermore, using in vitro analytical methods, we confirmed the ability of our Atomic Layering and Thermostable Antigen and Adjuvant (ALTA(R)) platform to impart thermostability upon the N332-GT5 gp140 antigen, a clinically relevant HIV-1 immunogen, indicating the potential for ALTA(R) formulation to generate thermostable, single-dose vaccine products. Highlights- ALTA(R) microparticles provide sustained antigen delivery with variable release rates, which can be controlled by altering ALD-coat thickness - Sustained antigen release from thermostable, spray-dried ALTA(R) vaccine products impacts kinetics of humoral and cellular responses, and improves antigen-specific immunogenicity compared to single administration of liquid vaccine - ALTA(R) formulation imparts vaccine thermostability through spray-drying and ALD-coating to clinically relevant HIV-1 Env antigen, N332-GT5 gp140

immunology↗

Deep and Quantitative Proteomic Profiling of Low Volume Mouse Serum Across the Lifespan

Assessing and validating circulating biomarkers is essential for the development of pre-clinical biomarkers that predict biological aging and aging-phenotypes in mice. However, comprehensive proteomics of serum, especially in longitudinal mouse studies, are limited by low volumes of samples. In this study, we develop a workflow for comprehensive and quantitative proteomic analysis of low volume mouse serum and demonstrate its utility and performance in identifying and evaluating key associations with aging phenotypes. Notably, a nanoparticle (NP)-based serum processing workflow coupled to mass spectrometry (MS) increases proteomic coverage by 3 to 6-fold across a range of volumes and provides a quantitative and reproducible (CV < 10%) pipeline for NP-based studies. In a study of 30 mice (aged 12, 24, and 30 months), we uncovered 3992 protein groups across all samples (2235 on average) in 20 {micro}L of serum and highlight novel insights into aging-associated changes in serum and associations with glucose and body composition. With 1 {micro}L additional serum, a 48-cytokine assay quantified 39 additional proteins not identified by MS. This study establishes a powerful workflow that enables deep quantitative proteomics of biologically relevant proteins in volumes feasibly obtained from mice (21 {micro}L of serum) and presents fundamental insights into the aging serum proteome.

biochemistry↗

Tuning the immunostimulation properties of cationic lipid nanocarriers for nucleic acid delivery

Nonviral systems, such as lipid nanoparticles, have emerged as reliable methods to enable nucleic acid intracellular delivery. The use of cationic lipids in various formulations of lipid nanoparticles enables the formation of complexes with nucleic acid cargo and facilitates their uptake by target cells. However, due to their small size and highly charged nature, these nanocarrier systems can interact in vivo with antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages. As this might prove to be a safety concern for developing therapies based on lipid nanocarriers, we sought to understand how they could affect the physiology of APCs. In the present study, we investigate the cellular and metabolic response of primary macrophages or DCs exposed to the neutral or cationic variant of the same lipid nanoparticle formulation. We demonstrate that macrophages are the cells affected most significantly and that the cationic nanocarrier has a substantial impact on their physiology, depending on the positive surface charge. Our study provides a first model explaining the impact of charged lipid materials on immune cells and demonstrates that the primary adverse effects observed can be prevented by fine-tuning the load of nucleic acid cargo. Finally, we bring rationale to calibrate the nucleic acid load of cationic lipid nanocarriers depending on whether immunostimulation is desirable with the intended therapeutic application, for instance, gene delivery or messenger RNA vaccines.

immunology↗

Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice

Tumor suppressor p53 mutations, with subsequent loss-of-tumor suppressive function and gain-of oncogenic functions, are associated with more than 50% of human cancers. Aggregation and amyloid formation are also mechanisms by which wild type and mutant p53 might be involved in cancer, but the direct evidence of how aggregated p53 acts as an oncogene is lacking. In this study, we directly demonstrate that wild-type p53 amyloid formation imparts oncogenic properties to normal cells. Cells with p53 amyloids show enhanced survival, apoptotic resistance with increased proliferation and migration rates. The tumorigenic potential of p53 amyloid transformed cells is further confirmed in a mice xenograft model, wherein the tumor showed p53 amyloid aggregates. Gene-expression analysis and proteomic profiling suggest that p53 amyloid formation triggers aberrant expression of pro-oncogenes while downregulating the tumor-suppressive genes. Interestingly, disaggregating p53 rescues the cellular transformation and also inhibits tumor development in mice. We propose that wild-type p53 amyloid formation can potentially contribute to the initiation of tumor development.

cancer biology↗